
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 5/5/2014

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction
of incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition

On May 5, 2014, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the first quarter ended March 31, 2014. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed to "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated May 5, 2014 titled "Dynavax Reports First Quarter 2014 Financial Results."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: May 5, 2014

By: /s/ DAVID JOHNSON
David Johnson
Vice President

EXHIBIT INDEX

**Exhibit
No.**

Description

EX-99.1

Press Release, dated May 5, 2014 titled "Dynavax Reports First Quarter 2014 Financial Results."

Contact:

Michael Ostrach
Chief Business and Principal Financial Officer
510-665-7257
mostrach@dynavax.com

**DYNAVAX REPORTS FIRST QUARTER 2014
FINANCIAL RESULTS**

BERKELEY, CA – May 5, 2014 – Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2014. The Company had \$177.7 million in cash, cash equivalents and marketable securities as of March 31, 2014.

For the quarter ended March 31, 2014, Dynavax reported total revenues of \$3.5 million compared to \$2.1 million for the first quarter of 2013. This increase primarily relates to the recognition of revenue under our collaboration agreement with AstraZeneca.

General and administrative expenses were \$4.2 million for the quarter ended March 31, 2014 compared to \$8.8 million for the first quarter of 2013. The 2013 three month period includes non-recurring cash and non-cash stock-based severance costs of \$2.5 million. Excluding these non-recurring organizational transition costs, general and administrative expenses decreased by 34% in the first quarter of 2014 compared to the first quarter of 2013.

Research and development expenses were \$13.2 million for the quarter ended March 31, 2014 compared to \$14.2 million for the first quarter of 2013. This decrease was primarily due to higher severance expenses, including non-cash stock-based compensation charges, in the 2013 period.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended March 31,	
	2014	2013
Revenues:		
Collaboration revenue	\$ 2,373	\$ 883
Grant revenue	1,125	760
Service and license revenue	-	442
Total revenues	3,498	2,085
Operating expenses:		
Research and development	13,231	14,164
General and administrative	4,157	8,800
Unoccupied facility expense	77	-
Total operating expenses	17,465	22,964
Loss from operations	(13,967)	(20,879)
Interest income	65	72
Interest expense	-	(32)
Other income	62	14
Net loss	\$ (13,840)	\$ (20,825)
Basic and diluted net loss per share	\$ (0.05)	\$ (0.11)
Shares used to compute basic and diluted net loss per share	262,826	182,847

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA
(In thousands)
(Unaudited)

	<u>March 31,</u> <u>2014</u>	<u>December 31,</u> <u>2013</u>
Assets		
Cash, cash equivalents and marketable securities	\$ 177,679	\$ 189,376
Property and equipment, net	8,584	8,706
Goodwill	2,576	2,579
Other assets	4,746	3,961
Total assets	<u>\$ 193,585</u>	<u>\$ 204,622</u>
Liabilities and stockholders' equity		
Deferred revenues	\$ 10,334	\$ 7,298
Other liabilities	9,398	11,030
Total liabilities	<u>19,732</u>	<u>18,328</u>
Stockholders' equity	<u>173,853</u>	<u>186,294</u>
Total liabilities and stockholders' equity	<u>\$ 193,585</u>	<u>\$ 204,622</u>